Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,892.45 +1,457.96 (+2.23%) CMC Crypto 200
1,369.64 -4.20 (-0.31%)
Sol-Gel Technologies Ltd. (SLGL)
After hours:
| Previous close | 0.7392 |
| Open | 0.7400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.6900 - 0.7500 |
| 52-week range | 0.6310 - 4.0500 |
| Volume | |
| Avg. volume | 30,487 |
| Market cap | 20.893M |
| Beta (5Y monthly) | 1.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Sol-Gel to receive a total consideration of up to US$15 million, out of which US$10 million will be paid as upfront and regulatory milestonesNESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today a
- GlobeNewswire
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Patent challenge initiated by Arcutis BiotherapeuticsNESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that Padagis Israel Pharmaceuticals Ltd (“Padagis”), Sol-Gel’s collaboration p
- GlobeNewswire
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib g
